9G2.SI stock down 8.33% to S$0.044 intraday 17 Mar 2026: key levels ahead

The 9G2.SI stock slipped 8.33% intraday to S$0.044 on 17 Mar 2026 on the SES, making it one of Singapore’s top losers today. Volume ran at 3,100,100 shares versus an average of 4,979,600, signalling heavier selling interest. The move follows weak fundamentals and low liquidity in the Healthcare, Medical – Care Facilities sector. As an AI-powered market analysis platform, Meyka AI flags the stock for short-term volatility while providing model-based forecasts to help form trading and risk plans.

9G2.SI stock intraday snapshot

One clear fact: Singapore Institute of Advanced Medicine Holdings Ltd. (9G2.SI) is trading at S$0.044, down S$0.004 (-8.33%) intraday on SES (Singapore). Today’s range was S$0.042–S$0.046 with market cap at S$47.07M and shares outstanding 1,045,900,200. Volume of 3,100,100 equals 0.68x relative volume, showing below-average turnover but still elevated selling pressure. The stock remains under its 50-day average S$0.052 and sits near its 200-day average S$0.043, highlighting short-term weakness.

Drivers of the decline and recent news

Today’s drop follows stretched valuation and lingering negative earnings momentum: EPS -0.02 and PE -2.25 signal persistent losses. No fresh corporate catalysts were announced; recent coverage compares 9G2.SI to regional healthcare peers. Investors citing competitor comparisons and thin liquidity have pushed the stock lower. See recent market comparisons and competitor reports for context source and regional peer analysis source.

Fundamentals, valuation and sector context for 9G2.SI stock

The company operates in Healthcare, Medical – Care Facilities, but key metrics are weak: price-to-book 1.11, price-to-sales 2.95, current ratio 0.27, and debt-to-equity 1.77. Working capital is negative S$16,944,687, and free cash flow per share is -0.0039. Against the Healthcare sector average PE of 21.21, 9G2.SI’s negative earnings and high leverage make it a higher risk name. These fundamentals explain part of the intraday selling and the stock’s inclusion among top losers.

Technicals and trading levels to watch for 9G2.SI stock

Technically, the stock shows mixed signals: RSI 50.89 indicates neutral momentum while ADX 30.45 points to a strong current trend. Key levels: immediate support near S$0.042 (today’s low and close to 200-day MA S$0.043), resistance at S$0.050–S$0.052 (50-day MA). On the intraday chart, traders should watch volume confirmation; average volume is 4,979,600, so sustained moves require higher turnover. Volatility is elevated given the stock’s YTD change of -38.36%.

Meyka AI grade and model forecasts for 9G2.SI stock

Meyka AI rates 9G2.SI with a score out of 100: 60.88 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly S$0.030, quarterly S$0.080, and yearly S$0.086. Versus the current S$0.044, that implies -31.82% to monthly, +81.82% to quarterly, and +95.45% upside to the yearly projection. Forecasts are model-based projections and not guarantees.

Risks, price targets and trading strategy for top losers

Primary risks: continued operating losses, high leverage, and thin liquidity that can amplify moves. Realistic near-term price targets: a conservative support target S$0.030 and a recovery target near the yearly forecast S$0.086 if fundamentals improve. For short-term traders, use tight stops and size positions for liquidity risk. For longer-term investors, demand clearer cash-flow improvement and debt reduction before upgrading exposure. The stock trades on SES (Singapore) and is subject to sector pressures in Healthcare.

Final Thoughts

9G2.SI stock is clearly under pressure intraday, trading at S$0.044 on 17 Mar 2026 after an 8.33% slide and 3,100,100 shares changing hands. Weak earnings, negative cash flow per share, and a high debt-to-equity ratio explain the selling. Technically, the stock sits just above its 200-day average and below the 50-day average, so short-term traders should treat rallies cautiously. Meyka AI’s forecast model projects a yearly S$0.086 (about +95.45% vs today), while the monthly S$0.030 implies -31.82% downside — a wide range that reflects high uncertainty. Our Meyka grade (60.88, Grade B, HOLD) reflects this split: the model sees recovery potential but fundamentals and liquidity create material downside risk. Investors should prioritise position sizing and confirm any rebound with higher volume and improved cash flow before increasing exposure. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.